ONCOLOGY Decoded

>

ONCOLOGY Decoded

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

2 experts are featured in this series.

Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Ben Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

2 experts are featured in this series.

Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Ben Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

2 experts are featured in this series.

Episode 1: NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Ben Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

2 experts are featured in this series.

Oncology Decoded: Genitourinary Cancer Therapies – Teaser

Manojkumar Bupathi, MD, MS;Ben Garmezy, MD
February 7th 2025

Manojkumar Bupathi, MD, MS, and Ben Garmezy, MD, discuss how to optimize treatment approaches for genitourinary cancers through evaluation of real-world data, sequencing strategies, and toxicity management while working to bridge care disparities between community and academic settings.